Document Detail


First clinical experience with isradipine in the treatment of hypertension in Portugal.
MedLine Citation:
PMID:  1720485     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The efficacy and safety of isradipine and nifedipine retard were compared in 51 patients with mild-to-moderate essential hypertension. A 4-week placebo run-in period was followed by an 8-week course of treatment. Patients were randomly allocated to either isradipine 1.25 mg twice daily (n = 24) or nifedipine 20 mg twice daily (n = 826); dosages were doubled if blood pressure was not normalized [diastolic blood pressure greater than or equal to 90 mm Hg) after 4 weeks of active treatment. Systolic/diastolic blood pressures were significantly reduced (p less than 0.01/p less than 0.01) by isradipine from 162/103 to 145/89 mm Hg, and by nifedipine from 162/104 to 143/88 mm Hg. Normalization rates were 79% with isradipine and 67% with nifedipine. It was necessary to double the dosage in seven of the patients taking isradipine and in three of those taking nifedipine; the mean final dosages were 1.63 mg and 22.4 mg twice daily, respectively. Heart rate did not change significantly with either treatment. There were drug-related adverse events in five patients (21%) taking isradipine (2 edema, 2 headache, 2 palpitations, 1 flushing) and in eight (30%) of those taking nifedipine (5 edema, 2 headache, 1 palpitations). Therapy was withdrawn in one patient in the isradipine group (1 headache) and two patients in the nifedipine group (1 edema, 1 headache). We conclude that isradipine is a highly effective and well tolerated antihypertensive agent.
Authors:
F Rocha-Gonçalves; G Mariano-Pego; J Viegas; J M Correia; M A Botelho
Related Documents :
6143505 - Hemodynamic effects of sublingual nifedipine in acute myocardial infarction.
17203115 - The effect of nifedipine on oral contraceptive-induced hypertension in rats.
3474215 - Echocardiographic assessment of anthracycline cardiotoxicity during different therapeut...
7282755 - Modification of left ventricular response to pacing tachycardia in nifedipine in patien...
12860135 - Characterization of the pressure-induced intermediate and unfolded state of red-shifted...
11568025 - Does histocompatibility affect homograft valve function after the ross procedure?
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  18 Suppl 3     ISSN:  0160-2446     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  1991  
Date Detail:
Created Date:  1992-01-09     Completed Date:  1992-01-09     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  S4-6     Citation Subset:  IM    
Affiliation:
Department of Cardiology, Faculty of Medicine, University of Oporto, Portugal.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antihypertensive Agents / adverse effects,  therapeutic use*
Blood Pressure / drug effects
Calcium Channel Blockers / adverse effects,  therapeutic use*
Dihydropyridines / adverse effects,  therapeutic use*
Double-Blind Method
Female
Heart Rate / drug effects
Humans
Hypertension / blood,  drug therapy*,  physiopathology
Isradipine
Male
Middle Aged
Nifedipine / therapeutic use
Portugal
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Calcium Channel Blockers; 0/Dihydropyridines; 21829-25-4/Nifedipine; 75695-93-1/Isradipine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Isradipine, a new calcium antagonist: effects on maternal and fetal hemodynamics.
Next Document:  Sleep disturbances in hypertension: a double-blind study between isradipine and metoprolol.